ArticleJournal of experimental & clinical cancer research : CR2026
Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs).
Gloria Ravegnini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.